anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The action of HCG is virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. Androgen stimulation in the male leads to the development of secondary sex characteristics and may stimulate testicular descent when no anatomical impediment to descent is present. This descent is usually reversible when HCG is discontinued. During the normal menstrual cycle, LH participates with FSH in the development and maturation of the normal ovarian follicle, and the mid-cycle LH surge triggers ovulation. HCG can substitute for LH in this function. During a normal pregnancy, HCG secreted by the placenta maintains the corpus luteum after LH secretion decreases, supporting continued secretion of estrogen and progesterone and preventing menstruation. HCG HAS NO KNOWN EFFECT ON FAT MOBILIZATION, APPETITE OR SENSE OF HUNGER, OR BODY FAT DISTRIBUTION.
The neuroinflammatory response triggered by cerebral ischemia-reperfusion injury (CIRI) is characterized by the upsurge of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, which promote leukocyte infiltration and subsequent accumulation in the ischemic zone. This accumulation further intensifies inflammation and aggravates ischemic damage. Certolizumab pegol (CZP), a monoclonal antibody targeting TNF-α, is widely used in treating various inflammatory diseases. This study explored the therapeutic potential of CZP in a mouse model of CIRI, induced by middle cerebral artery occlusion (MCAO), focusing on its influence on the microglial inflammatory response. In vitro analyses revealed that CZP markedly inhibits TNF-α-stimulated inflammation in primary microglia with an EC50 of 1.743 ng/mL. In vivo, MCAO mice treated with CZP (10 μg/mouse, i.p.) for 3 days showed reduced infarct volume, partially improved neurological function, and diminished blood-brain barrierdisruption. Additionally, CZP treatment curtailed microglial activation and the release of pro-inflammatory mediators in the early stages of stroke. It also favorably modulated microglial M1/M2 polarization, rebalanced Th17/Treg cells dynamics, and inhibited Caspase-8-mediated GSDMD cleavage, preventing microglial pyroptosis. Collectively, this study described that the treatment with CZP reversed damaging process caused by CIRI, offering a promising therapeutic strategy for the treatment of ischemic stroke.
Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
The relations between degrees of chronic kidney disease (CKD) and congestive heart failure (CHF) events after percutaneous coronary intervention (PCI) are not well characterized. We sought to determine the relation between different stages of CKD and acute CHF events, including HF and cardiogenic shock (CS), and the impact of CKD stages on all-cause mortality after PCI. Patients who underwent PCI from 2009 to 2017 were identified from our institution's National Cardiovascular Disease Registry CathPCI Database. Patients were stratified by CKD stage 1 (estimated glomerular filtration rate [eGFR] ≥90 ml/min/1.73 m2), 2 (60 to 89), 3a (45 to 59), 3b (30 to 44), 4 (16 to 29), 5 (≤15), and current dialysis. The primary end point was composite HF events defined as acute HF or CS within 30 days after PCI, or in-hospital mortality, stratified by CKD and analyzed by multivariable regression after screening with univariate analysis (p <0.05 entry criteria). Patients with CKD stage 3a or worse had more composite HF events, with an increase in all components, compared with patients with CKD stages 1 to 2 (p <0.0001 for all comparisons). After multivariable adjustment, CKD stages 3a to 5 remained independent predictors of composite HF or in-hospital mortality events. eGFR remained a strong predictor of acute HF events after multivariable adjustment, with a model including eGFR and baseline and procedural characteristics achieving excellent discriminatory ability with area under the curve 0.92. In conclusion, baseline eGFR is a strong, independent predictor of acute HF events after PCI. CKD stages 3a to 5 independently predict HF events including HF decompensation and CS and are predictors of in-hospital mortality after PCI. Patients with baseline CKD may benefit from targeted interventions to limit acute HF events after PCI.
In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961, 100 ug, will be administered via intravenous infusion.
The lifetime prevalence of chronic neck pain is approximately 50%, and it is associated with substantial societal and individual burden. Neck pain is prevalent among healthcare workers, specifically among nurses. About 45% of nurses experience neck pain, but rates may vary by population and nursing type. Neck pain in nurses significantly contributes to sickness absence and negatively impacts nurses' productivity and performance at work. Neck pain is a burden on nurses' individual health and on the healthcare system as a whole. Two of the most common non-pharmacological approaches for the management of neck pain are exercise and manual therapies, and there is some evidence that multimodal approaches combining the two are more effective than unimodal strategies. Given the widespread availability in most metropolitan areas of both Tai Chi and chiropractic care, development of an evidence-based care regimen integrating Tai Chi mind-body self-care with chiropractic represents a practical strategy for management of neck pain.

To help inform the design of a larger-scale trial evaluating the combined effects of Tai Chi and chiropractic care for neck pain, the investigators propose to conduct a single-arm pilot study to evaluate the feasibility of delivering coordinated chiropractic care and Tai Chi via community-practitioners for nurses at Mass General Brigham Hospitals with chronic neck pain. 21 nurses with chronic neck pain that meet all study eligibility criteria will be recruited to receive 10 chiropractic treatments and weekly Tai Chi training over 16 weeks.
PURPOSE:The tilted pharmaceutical preparation coated with a film, comprising a methacrylic acid-acrylic acid ethyl ester copolymer and glyceryl triacetate as main components. CONSTITUTION:100pts.wt. methacrylic acid-acrylic acid ethyl ester copolymer (an average molecular weight of about 250,000) shown by the formula is blended with 0.5-7.5pts.wt., preferably 1.0-5.0pts.wt. glyceryl triacetate, to give a film of an enteric solid pharmaceutical preparation. An enzyme such as especially pancreatin, elastase, etc. may be cited as a drug which is needed to be made into an enteric pharmaceutical preparation. To coat tablets, tablets are sprayed with an aqueous dispersion while being rotated in a coating pan such as a high coater, and subjected to hot-air drying. To coat granules, granules are sprayed with an aqueous dispersion while being made to flow by hot air by a fluid coater, and subjected to hot-air drying.
The product is manufactured by heating together a physiologically acceptable salt, or salts, of iron (Fe) and a  lipid,  or lipids.  It is  for topical cutaneous application  as  a  prophylactic,  diagnostic aid and/or remedy during the latent or clinical stage of systemic lupus     erythematosus,     vasculitis,     sarcoidosis, amyloidosis, rheumatoid arthritis, osteoarthrosis, acne, comedos,  psoriasis,  tinea,  onychia,  paronychia,  corns, callosities, alopecia and indolent tropical ulcers. The novelty of the invention lies in the ability of the said product  to  elicit  a  skin  reaction  at  the latency-reactivation  sites  where  the  causative  agent  of  the above-mentioned maladies resides,  while bringing on no such reaction in the rest of the skin. Hitherto it has not  been  known,  nor  used,  in  the  art  that  such composition  of  matter  applied  onto  the  skin  of susceptible  subjects  can  at  first  elicit  pustules, papules and/or weals,  then heal resulting ulcers,  and that  with  their  débriding  and  the  removal  of  the necrosed tissue of the latency-reactivation sites it is feasible  to  eradicate  the  causative  agent  (primary stimulus,  persistent  antigen)  from  the  skin,  thus healing the  lesions and  arresting the development of these  maladies  at  that  particular  stage.  The  said product  may  also  prove  useful  in  research  into  the above-mentioned and other maladies.  The skin reaction the said product can elicit serves as an indicator of the above-mentioned maladies during their asymptomatic latent period.
The present invention provides loselofen sodium injection and its preparation. Available loselofen sodium dosage forms include oral tablet, capsule and granule only. The Rosorolfine sodium injection of the present invention is used for relieving pain and diminishing inflammation of chronic rheumatic arthritis, rheumatoid arthritis, lumbago, etc. and especially relieving serious pain of postoperation, fracture, strain, etc. It has obvious effects and no addiction. It is prepared by dissolving Rosorolfine sodium in water, adding proper amount of medicinal supplementary material, eliminating pyretogen, disinfection or filtering and may be prepared into water injection, transfusion agent to freezed dried powder for injection.
This was an unblinded, parallel-group, superiority trial that randomized participants in a balanced (1:1) allocation ratio. We made no changes to our protocol after we began enrollment. Nor did we conduct any interim analyses. Each morning of the study period, including weekends and holidays, investigators listed all consecutive patients who were newly referred for SE by participating hospitalists. After hospitalists completed their initial evaluation of each patient, which included a history, physical exam, and review of medical records, investigators asked them to choose their indications for SE from a closed list. Given these indications, investigators then asked if HCUE could help them to assess their patients; if not, investigators excluded such patients. Finally, hospitalists were asked for their current management plans, which included medication regimens, diagnostic tests, specialty consultations, and timing of hospital discharge. If hospitalists remained masked to any preliminary SE results, investigators assigned participants who gave written informed consent to an intervention group. We used a computer-generated list of random numbers for the allocation sequence, and we concealed the sequence in an on-site computer system that only released allocations to investigators after they entered participant identifiers.

Hospitalists either awaited SE results for participants randomized to usual care or they performed HCUE for participants randomized to HCUE-guided care. Hospitalists performed HCUE with a MicroMaxx 3.4 hand-carried ultrasound machine equipped with a cardiology software package and a 1 to 5 MHz P17 cardiac transducer (Sonosite, Inc., Bothell, WA). The details of the HCUE protocol are described elsewhere. In brief, without assistance from nursing staff, hospitalists positioned participants on standard hospital beds and recorded 7 best-quality images up to 6 seconds in duration. Then hospitalists replayed the images for immediate interpretation. They made linear measurements with a caliper held directly to the ultrasound monitor and translated them into qualitative assessments based on simplified standard values.

The primary outcome was the length of stay on the short stay unit or general medicine ward service of the referring hospitalist. The duration began when the patient was admitted to the hospitalist service and ended when the patient was discharged home or transferred to a different service in the hospital. We chose this duration, rather than the length of stay of the entire hospitalization, because we wanted the primary outcome to reflect how HCUE affected hospitalists' management decisions in the hospital, including the transfer of participants to other services.
Teratogenic Effects:

There are no adequate and well-controlled studies of topically administered tacrolimus in pregnant women. The experience with tacrolimus ointment when used by pregnant women is too limited to permit assessment of the safety of its use during pregnancy.

Reproduction studies were carried out with systemically administered tacrolimus in rats and rabbits. Adverse effects on the fetus were observed mainly at oral dose levels that were toxic to dams. Tacrolimus at oral doses of 0.32 and 1.0 mg/kg (0.04X to 0.12X MRHD based on BSA) during organogenesis in rabbits was associated with maternal toxicity as well as an increase in incidence of abortions. At the higher dose only, an increased incidence of malformations and developmental variations was also seen. Tacrolimus, at oral doses of 3.2 mg/kg during organogenesis in rats, was associated with maternal toxicity and caused an increase in late resorptions, decreased numbers of live births, and decreased pup weight and viability. Tacrolimus, given orally at 1.0 and 3.2 mg/kg (0.04X to 0.12X MRHD based on BSA) to pregnant rats after organogenesis and during lactation, was associated with reduced pup weights.

No reduction in male or female fertility was evident.

There are no adequate and well-controlled studies of systemically administered tacrolimus in pregnant women. Tacrolimus is transferred across the placenta. The use of systemically administered tacrolimus during pregnancy has been associated with neonatal hyperkalemia and renal dysfunction. Tacrolimus ointment should be used during pregnancy only if the potential benefit to the mother justifies a potential risk to the fetus.
Participants will receive generic placemats listing all of the restaurant's kids' meals. Families will also receive a generic frequent diner card, which after purchasing (any) kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period. Corresponding signage will be displayed in the restaurant.
<P>PROBLEM TO BE SOLVED: To provide sodium phlogopite powder scarcely containing impurity, having high cation exchange capability and swelling property and hardly causing elution of fluoride ion.  <P>SOLUTION: The synthetyic sodium phlogopite exhibits 50 meq/100g cation exchange capacity (CEC) and ≤1,000 ppm fluoride ion elution in a hot water elution test at 100°C for 1 hr. The powder is manufactured by melting a raw material mixture by high frequency induction heating. In the method, an oxide, carbonate or fluoride of Na, Mg, Al and Si are mixed so that the ratio of Na, Mg, Al, Si and F in the raw material mixture is 95 to 105 mol% of the theoretical formula composition of the synthetic sodium phlogopite to be used. The elution of fluorine ions is controlled to ≤20 ppm by further heating the resultant synthetic sodium phlogopite powder to 600 to 1,350°C.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
One of the most challenging roles a physician can serve is delivering life altering and/or bad news to patients and their families, and yet this skill is not widely taught to physicians. A survey from 2003 of pediatric residents found that not only was there minimal education and training in this area, but that they felt there was no natural improvement in their skills from the first to third year of training. It has also been shown that the art of eliciting a patient or family's concerns about death and responding to them is felt to be poorly taught. Worse, residents have indicated that a hidden curriculum in medicine seems to indicate that there is no value to these conversations at all. Residents are not the only stakeholders involved who have expressed concern with this reality. Parents of pediatric patients have repeatedly reported wanting increased sensitivity and clarity during sharing of life-altering information. Up to 75% of parents have reported a negative experience involving end of life (EOL) discussions, and cited inexperience, lack of comfort in communication, and a lack of knowledge as contributing factors to their negative experiences. Less than 18% of students and residents report receiving formal education in EOL discussions, despite the fact that 90% or more of residents have identified caring for those dying as part of a physician's responsibilities. Of residents who do get experience with EOL discussions, less than 2/3 receive feedback. Some residencies, such as internal medicine, have recognized the need for formal instruction on how to have EOL discussions is needed and have implemented formal programs to answer it, and it has even become a standard expectation for many fellowships. Formal education regarding EOL has also become a standard expectation for many fellowships, including pediatric neonatology, intensive care, and hematology/oncology. Despite the evidence that there is need for formal intervention and education regarding EOL care, there has been little advancement towards implementing a formal curriculum in pediatric residency programs. Review of the literature demonstrates that only one study has developed a formal curriculum involving a method called SPIKES (Setting, Perception, Involvement, Knowledge, Empathy, and Summary) that targets pediatric residents. The initial data from this study is promising and indicates increased comfort level in residents. However, to date no study has evaluated if the method of instruction affects the resident education, an important consideration as some interventions (ex. standardized patients) are more costly and time consuming than others (ex. facilitator guided small group sessions).
BACKGROUND: Sarcopenia has a negative impact on the number of populations. The frequency of sarcopenia in polytrauma patients, however, is little understood. Knowing how many people face a bad outcome will raise awareness and help stop additional muscle mass loss.
AIM: This pilot study's objectives included determining prevalence of the low mass of muscle in the aged patients of poly-trauma and examining the links between complications, low muscle mass, death, and the inflammatory response.
METHOD: All polytrauma patients who were seen between 2017 and 2021 at the level-I trauma centre were included in the data from the regional perspective registry of trauma. The computed tomography (CT) of the abdomen's availability and the height in the subjects was screened to determine the skeletal mass index (SMI), which is utilised to calculate the sarcopenia. Additionally, factors of clinical outcome were evaluated. A multivariate regression analysis was conducted if parameters related to a poor result were found through a univariate analysis.
RESULTS: Sarcopenia was prevalent in 33.5 percent of the population overall, but in older age groups (60-79 years), it was significantly more prevalent, reaching to 82 percent in the individuals over the 80 years old. The ISS (Injury severity score) where the p=0.026, age where the p<0.0001, the CCI (Charlson comorbidity index) where the p=0.001, injury severity score, and the 30-day or the in-hospital mortality were all associated with sarcopenia. The Injury Severity Score (ISS) is a medical scoring system to assess trauma severity based on the extent of injuries in various body regions. Sarcopenia was discovered to be a predictor of the 30-day mortality by log rank analysis (p=0.032).
CONCLUSION: In conclusion, we found that polytrauma patients had a significant prevalence of sarcopenia, which increased with age. Additionally, sarcopenia was found to be the predictor of the 30-day death, highlighting clinical importance of finding the low muscle mass on the CT-scan, which was already regularly performed on the majority of patients of trauma.
An isolated antibody or one of its functional fragments able to bond with human Insulin-like Growth Factor-I Receptor (IGF-IR) and, if necessary, inhibit the natural fixing of IGF1 and/or IGF2 ligands and/or capable of specifically inhibiting the tyrosine kinase activity of the IGF-IR receptor, is new. A new isolated antibody or one of its functional fragments is able to bond with human Insulin-like Growth Factor-I Receptor (IGF-IR) and, if necessary, inhibit the natural fixing of IGF1 and/or IGF2 ligands and/or is capable of specifically inhibiting the tyrosine kinase activity of the IGF-IR receptor. It comprises a light chain with at least one CDR (complementarity-determining region) determining the complementarity selected from the CDRs of SEQ ID No: 1, 2, 3 sequences or at least one CDR with its sequence being at least 80 per cent identical after optimal alignment with the SEQ ID No: 1, 2 or 3 sequences, and/or a heavy chain with at least one CDR selected from the CDRs of sequences SEQ ID No: 4, 5 and 6, or at least one CDR having at least 80 per cent identity after optimal alignment with the SEQ ID No: 4, 5 and 6 sequences. The antibody, called 13F5, comprises a heavy chain with the amino-acid sequence SEQ ID No: 20 and a light chain containing the amino acid sequence SEQ ID No: 19. All the sequences are given in the specification. - ACTIVITY : Cytostatic. - MECHANISM OF ACTION : IGF-IR antagonist.
Before initiating therapy, a detailed history and physical examination should be made.

Carbamazepine should be used with caution in patients with a mixed seizure disorder that includes atypical absence seizures, since in these patients carbamazepine has been associated with increased frequency of generalized convulsions (see INDICATIONS AND USAGE). 

Therapy should be prescribed only after critical benefit-to-risk appraisal in patients with a history of cardiac, hepatic, or renal damage; adverse hematologic reaction to other drugs; or interrupted courses of therapy with carbamazepine.

Hyponatremia, Syndrome of Inappropriate Antidiuretic Hormone Secretion, and Water Intoxication

Hyponatremia can occur as a result of treatment with carbamazepine. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine treatment may be dose-related. Elderly patients may be at greater risk of developing hyponatremia. Patients treated with diuretics can be at greater risk. Consider discontinuing carbamazepine in patients with symptomatic hyponatremia. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.
Take lisdexamfetamine dimesylate capsules orally in the morning with or without food; avoid afternoon doses because of the potential for insomnia. Lisdexamfetamine dimesylate capsules may be administered in one of the following ways:

Information for lisdexamfetamine dimesylate capsules: 

  * Swallow lisdexamfetamine dimesylate capsules whole, or
  * Open capsules, empty and mix the entire contents with yogurt, water, or orange juice. If the contents of the capsule include any compacted powder, a spoon may be used to break apart the powder. The contents should be mixed until completely dispersed. Consume the entire mixture immediately. It should not be stored. The active ingredient dissolves completely once dispersed; however, a film containing the inactive ingredients may remain in the glass or container once the mixture is consumed.



Lisdexamfetamine dimesylate capsules can be substituted with lisdexamfetamine dimesylate chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet) [see Clinical Pharmacology (12.3)].

Do not take anything less than one capsule per day. A single dose should not be divided.